CNBG’s Inactivated Coronavirus Vaccine Program Wins Gold Prize at the First MSTOC
The Development Center for Medical Science and Technology under the National Health Commission of China held the first Medical Science and Technology Innovation Competition (MSTOC) this year, with an aim to fuel innovation in medical science and technology, build a medical innovation ecosystem, strengthencoordination and cooperation of high-caliber medical professionals, research institutions, leading enterprises and academic organizations, sift out medical innovations with the greatest influence and potential, facilitate information exchange related to medical science and technology, and promote industrialization of excellent research projects.
Since its launch on May 9, 2020, MSTOC has drawn wide attention. A total of 428 candidate projects from 205 institutions, covering medical institutions, healthcare research institutions, and enterprises, participated in the competition. Entries involve medicines, medical instruments, and medical technologies. The “inactivated coronavirus vaccine” project of China National Biotec Group (CNBG) under Sinopharm passed the preliminary round, semi-final and final in the past six months, and eventually won a gold prize at the first MSTOC after thorough reviews by more than 80 experts from fields like medicine, engineering, industry, and investment.
On November 28, the award ceremony of the first MSTOC was held in Shenzhen. Yang Xiaoming, chairman of CNBG, attended the ceremony.
Innovation in medical science and technology is the core driving force for building a “Healthy China” and invigorating the country through science and technology. On April 12, the inactivated coronavirus vaccine developed by CNBG’s Wuhan Institute of Biological Products Co., Ltd. was approved for domestic simultaneous phase-I and II clinical trials. On April 27, the inactivated coronavirus vaccine developed by Beijing Institute of Biological Products Co., Ltd. was also approved for clinical trials, ensuring a
belt-and-braces approach for the development of coronavirus vaccines. A total 4,064 people at various ages were inoculated as part of the domestic phase-I and II clinical trials. Results of double-blind placebo experiments showed that both vaccines are highly safe, without any obvious adverse reaction cases reported, and those who received vaccination all show high-titer immunological response, regardless of age, vaccination procedure and dosage. The two vaccines developed by CNBG have been under phase-III clinical trials in countries including the UAE, Bahrain, Egypt, Morocco, Peru and Argentina. So far, more than 50,000 people have been inoculated with the vaccines, with the inoculated sample population covering 125 countries.